Our new Marketplace Crash Course is here to help. Sign-up for free, learn at your own pace.
Activist investor William Ackman has set his eyes on a new target: Allergan.
Ackman has joined forces with Valeant Pharmaceuticals to purchase the Botox-maker for an undisclosed amount — $50 billion is one educated guess. Ackman along with other so-called corporate raiders Carl Icahn and Nelson Peltz, have become famous, and sometimes infamous, for shaking up the companies they invest in.
Do they do more harm than good?
Bloomberg News reporter Tara Lachapelle joins Marketplace Morning Report host David Brancaccio to discuss the track record of activist investors, noting that more often than not, these in-it-to-win-it investors are actually a shareholder’s friend.
Click on the audio player above to hear more.
There’s a lot happening in the world. Through it all, Marketplace is here for you.
You rely on Marketplace to break down the world’s events and tell you how it affects you in a fact-based, approachable way. We rely on your financial support to keep making that possible.
Your donation today powers the independent journalism that you rely on. For just $5/month, you can help sustain Marketplace so we can keep reporting on the things that matter to you.